The Library
Browse by Warwick Author
Up a level |
Number of items: 9.
Connor, Charlotte, MBH, Yap, Warwick, Jane, Birchwood, M. J., De Valliere, Nicole, Madan, Jason, Melvin, Glenn A., Padfield, Emma, Patterson, Paul, Petrou, Stavros, Raynes, K., Stewart-Brown, Sarah L. and Thompson, Andrew D. (2022) An online parenting intervention to prevent affective disorders in high-risk adolescents : the PIPA trial protocol. Trials, 23 (1). 655. doi:10.1186/s13063-022-06563-8 ISSN 1745-6215.
Earl, Helena, Hiller, Louise, Vallier, Anne-Laure, Loi, Shrushma, McAdam, Karen, Hughes-Davies, Luke, Rea, Daniel, Howe, Donna L., Raynes, Kerry, Higgins, Helen B. et al.
(2020)
Six versus 12 monthsβ adjuvant trastuzumab in patients with HER2-positive early breast cancer : the PERSEPHONE non-inferiority RCT.
Health Technology Assessment, 24
(40).
pp. 1-190.
doi:10.3310/hta24400
ISSN 1366-5278.
Drayson, Mark T., Bowcock, Stella, Planche, Tim, Iqbal, Gulnaz, Pratt, Guy, Yong, Kwee, Wood, Jill, Raynes, Kerry, Higgins, Helen, Dawkins, Bryony, Meads, David, Hulme, Claire T., Whittaker, Anna C., Hawkey, Peter, Low, Eric and Dunn, Janet A. (2019) Prophylactic levofloxacin to prevent infections in newly diagnosed symptomatic myeloma: the TEAMM RCT. Health Technology Assessment, 23 (62). pp. 1-94. doi:10.3310/hta23620 ISSN 2046-4924.
Drayson, Mark T, Bowcock, Stella, Planche, Tim, Iqbal, Gulnaz, Pratt, Guy, Yong, Kwee, Wood, Jill, Raynes, Kerry, Higgins, Helen B., Dawkins, Bryony et al.
(2019)
Levofloxacin prophylaxis in patients with newly diagnosed myeloma (TEAMM) : a multicentre, double-blind, placebo-controlled, randomised, phase 3 trial.
The Lancet. Oncology, 20
(12).
pp. 1760-1772.
doi:10.1016/S1470-2045(19)30506-6
ISSN 1470-2045.
Earl, Helena M., Hiller, Louise, Vallier, Anne-Laure, Loi, Shrushma, McAdam, Karen, Hughes-Davies, Luke, Harnett, Adrian N, Ah-See, Mei-Lin, Simcock, Richard, Rea, Daniel et al.
(2019)
6 versus 12 months of adjuvant trastuzumab for HER2-positive early breast cancer (PERSEPHONE) : 4-year disease-free survival results of a randomised phase 3 non-inferiority trial.
The Lancet, 393
(10191).
pp. 2599-2612.
doi:10.1016/S0140-6736(19)30650-6
ISSN 0140-6736.
Chicca, I. J., Heaney, J. L. J., Iqbal, Gulnaz, Bowcock, S., Planche, T., Wood, J., Raynes, K., Hawkey, P., Pratt, G., Yong, K., Dunn, Janet A. and Drayson, M. T. (2018) Major changes in levels of regulatory cytokines and functional antibodies contribute to severe immunodeficiency of myeloma patients and persist at one year post diagnosis. Haematologica, 103 (Supplement 1). pp. 1-48. P02. ISSN 0390-6078
Bowcock, S., Atkin, C., Iqbal, Gulnaz, Yong, K., Pratt, G., Planche, T., Wood, J., Raynes, K., Hawkey, P., Dunn, Janet A., Drayson, M. and Co-Investigators, Teamm (2018) Does a long diagnostic pathway in myeloma lead to more advanced disease at presentation? An analysis from the TEAMM trial (Tackling EArly Morbidity and Mortality in Myeloma). British Journal of Haematology, 181 (Supplement 1). pp. 5-211. BSH18-PO-098 [pp 99]. ISSN 0007-1048 doi:10.1111/bjh.15226
Bowcock, S., Planche, T., Iqbal, Gulnaz, Pratt, G., Yong, K., Wood, J., Raynes, K., Hawkey, P., Dunn, Janet A., Drayson, M. and Co-Investigators, Teamm (2018) Levofloxacin prophylaxis in newly diagnosed myeloma reduces febrile episodes and death without increasing healthcare associated infections : results from the TEAMM trial (Tackling EArly Morbidity and Mortality in Myeloma). British Journal of Haematology, 181 (Supplement 1). pp. 5-211. BSH18-OR-012 [pp16]. ISSN 0007-1048 doi:10.1111/bjh.15226
Atkin, C., Drayson, M., Iqbal, Gulnaz, Yong, K., Pratt, G., Planche, T., Wood, J., Raynes, K., Higgins, Helen B., Dunn, Janet A. and Bowcock, S. (2018) Presenting symptoms of patients with multiple myeloma : data from the TEAMM (Tackling EArly Morbidity and Mortality in Myeloma) trial. British Journal of Haematology, 181 (Supplement 1). pp. 5-211. BSH18-PO-094 [pp 96]. ISSN 0007-1048 doi:10.1111/bjh.15226
This list was generated on Wed Apr 24 03:33:08 2024 BST.